What is Gesynta Pharma?
Founded in 2017, Gesynta Pharma is a biopharmaceutical company rooted in Nobel Prize-winning research from the Karolinska Institutet. The company's lead drug candidate, GS-248, is designed to reduce inflammation and enhance microvessel blood flow, offering potential new treatments for severe diseases. Currently, GS-248 is undergoing a comprehensive Phase II program to assess its efficacy in normalizing blood flow and alleviating pain in patients with systemic sclerosis, an autoimmune disease. The promising results from these ongoing and planned studies may pave the way for broader development into other indications, including cardiovascular and rheumatic diseases beyond systemic sclerosis.
How much funding has Gesynta Pharma raised?
Gesynta Pharma has raised a total of $79.8M across 3 funding rounds:
Other Financing Round
$20.5M
Other Financing Round
$27.8M
Series B
$31.5M
Other Financing Round (2020): $20.5M with participation from Hadean Ventures
Other Financing Round (2025): $27.8M led by Stephen Industries, Amboy Street Ventures, Catalyze Capital, Industrifonden, Linc, Hadean Ventures, and Innovestor
Series B (2025): $31.5M supported by Innovestor and HealthCap Partners
Key Investors in Gesynta Pharma
HealthCap Partners
HealthCap Partners is a private equity firm that provides growth capital and real estate solutions for the healthcare industry, focusing on facilitating buy-outs, recapitalizations, and strategic real estate initiatives.
Innovestor
Innovestor is a Finnish investment manager specializing in venture capital, real estate, and energy storage, with a focus on early-stage technology and life science startups.
Industrifonden
Industrifonden is a Swedish venture capital fund that invests in unique, scalable innovations aimed at improving society through breakthrough technologies and science, particularly in deep tech and life sciences.
What's next for Gesynta Pharma?
The recent strategic investment positions Gesynta Pharma for accelerated growth and the advancement of its therapeutic pipeline. With a focus on leveraging its foundational research, the company is poised to expand its clinical trials and explore new therapeutic avenues. The backing from prominent investors suggests confidence in Gesynta Pharma's scientific approach and its potential to address significant unmet medical needs in areas such as autoimmune, cardiovascular, and rheumatic diseases. This funding will be critical in navigating the complex regulatory pathways and scaling operations to bring its innovative treatments to market.
See full Gesynta Pharma company page
